Gene: Ly96 (lymphocyte antigen 96) Rattus norvegicus
Analyze
Symbol:
Ly96
Name:
lymphocyte antigen 96
Description:
Predicted to have lipopolysaccharide receptor activity. Predicted to be involved in several processes, including positive regulation of lipopolysaccharide-mediated signaling pathway; response to lipopolysaccharide; and toll-like receptor 4 signaling pathway. Predicted to localize to the intrinsic component of plasma membrane and lipopolysaccharide receptor complex. Orthologous to human LY96 (lymphocyte antigen 96); PARTICIPATES IN Toll-like receptor signaling pathway; toxoplasmosis pathway; INTERACTS WITH 1-naphthyl isothiocyanate; 4,4'-diaminodiphenylmethane; amphetamine.
Type:
protein-coding
RefSeq Status:
PROVISIONAL
Also known as:
LPS co-receptor MD-2; MD-2; MD2
Orthologs:
Latest Assembly:
Rnor_6.0 - RGSC Genome Assembly v6.0
NCBI Annotation Information:
Annotation category: partial on reference assembly
Position:
Rat Assembly Chr Position (strand) Source Genome Browsers JBrowse NCBI UCSC Ensembl Rnor_6.0 5 1,972,212 - 1,989,448 (-) NCBI Rnor6.0 Rnor_6.0 rn6 Rnor6.0 Rnor_5.0 5 1,967,544 - 1,984,775 (-) NCBI Rnor5.0 Rnor_5.0 rn5 Rnor5.0 RGSC_v3.4 5 1,701,969 - 1,705,247 (-) NCBI RGSC3.4 rn4 RGSC3.4 Celera 5 2,204,184 - 2,228,082 (-) NCBI Celera Cytogenetic Map 5 q11 NCBI
JBrowse:
View Region in Genome Browser (JBrowse)
Model
Imported Annotations - ClinVar
Charcot-Marie-Tooth disease axonal type 2K ISO RGD:1349135 8554872 ClinVar Annotator: match by term: Charcot-Marie-Tooth disease type 2K ClinVar PMID:15805163 more ... Charcot-Marie-Tooth disease type 4A ISO RGD:1349135 8554872 ClinVar Annotator: match by term: Charcot-Marie-Tooth disease, type 4A ClinVar PMID:28492532
Imported Annotations - CTD
carcinoma ISO RGD:1349135 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:22180778 cholestasis ISO RGD:1349135 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:27989131 Colorectal Neoplasms ISO RGD:1349135 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:22180778 Experimental Liver Cirrhosis ISO RGD:1349135 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:25380136 Neoplasm Metastasis ISO RGD:1349135 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:22180778 rheumatoid arthritis ISO RGD:1349135 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:17379860
(-)-demecolcine increases expression ISO RGD:1349135 6480464 Demecolcine results in increased expression of LY96 mRNA CTD PMID:23649840 1-naphthyl isothiocyanate increases expression EXP 6480464 1-Naphthylisothiocyanate results in increased expression of LY96 mRNA CTD PMID:25380136 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1623303 6480464 Tetrachlorodibenzodioxin affects the expression of LY96 mRNA CTD PMID:21570461 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO RGD:1349135 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of LY96 mRNA CTD PMID:28628672 4,4'-diaminodiphenylmethane increases expression ISO RGD:1623303 6480464 4, 4'-diaminodiphenylmethane results in increased expression of LY96 mRNA CTD PMID:18648102 4,4'-diaminodiphenylmethane increases expression EXP 6480464 4, 4'-diaminodiphenylmethane results in increased expression of LY96 mRNA CTD PMID:25380136 , PMID:30723492 4,4'-sulfonyldiphenol multiple interactions ISO RGD:1349135 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of LY96 mRNA CTD PMID:28628672 4-hydroxynon-2-enal increases expression ISO RGD:1623303 6480464 4-hydroxy-2-nonenal results in increased expression of LY96 mRNA CTD PMID:19191707 adenosine increases expression ISO RGD:1349135 6480464 Adenosine results in increased expression of LY96 mRNA CTD PMID:21538184 aflatoxin B1 affects expression ISO RGD:1349135 6480464 Aflatoxin B1 affects the expression of LY96 protein CTD PMID:20106945 aflatoxin B1 increases expression ISO RGD:1349135 6480464 Aflatoxin B1 results in increased expression of LY96 mRNA CTD PMID:21632981 , PMID:21641981 aflatoxin B2 decreases methylation ISO RGD:1349135 6480464 aflatoxin B2 results in decreased methylation of LY96 intron CTD PMID:30157460 amphetamine increases expression EXP 6480464 Amphetamine results in increased expression of LY96 mRNA CTD PMID:30779732 antirheumatic drug decreases expression ISO RGD:1349135 6480464 Antirheumatic Agents results in decreased expression of LY96 mRNA CTD PMID:24449571 arsenous acid increases expression ISO RGD:1349135 6480464 Arsenic Trioxide results in increased expression of LY96 mRNA CTD PMID:26705709 , PMID:27829220 arsenous acid multiple interactions ISO RGD:1349135 6480464 [Arsenic Trioxide co-treated with Bortezomib] results in increased expression of LY96 mRNA CTD PMID:25913414 azathioprine increases expression ISO RGD:1349135 6480464 Azathioprine results in increased expression of LY96 mRNA CTD PMID:22623647 benzo[a]pyrene increases expression ISO RGD:1623303 6480464 Benzo(a)pyrene results in increased expression of LY96 mRNA CTD PMID:22228805 benzo[a]pyrene affects methylation ISO RGD:1349135 6480464 Benzo(a)pyrene affects the methylation of LY96 intron CTD PMID:30157460 benzo[a]pyrene increases expression ISO RGD:1349135 6480464 Benzo(a)pyrene results in increased expression of LY96 mRNA CTD PMID:20106945 more ... benzo[e]pyrene decreases methylation ISO RGD:1349135 6480464 benzo(e)pyrene results in decreased methylation of LY96 intron CTD PMID:30157460 bis(2-chloroethyl) sulfide increases expression ISO RGD:1349135 6480464 Mustard Gas results in increased expression of LY96 mRNA CTD PMID:25102026 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of LY96 mRNA CTD PMID:25181051 bisphenol A increases expression ISO RGD:1349135 6480464 bisphenol A results in increased expression of LY96 mRNA CTD PMID:25047013 , PMID:27685785 bortezomib multiple interactions ISO RGD:1349135 6480464 [arsenic trioxide co-treated with Bortezomib] results in increased expression of LY96 mRNA CTD PMID:25913414 butanal increases expression ISO RGD:1349135 6480464 butyraldehyde results in increased expression of LY96 mRNA CTD PMID:26079696 cadmium atom increases expression ISO RGD:1349135 6480464 Cadmium results in increased expression of LY96 mRNA CTD PMID:21120746 cadmium dichloride increases methylation EXP 6480464 Cadmium Chloride results in increased methylation of LY96 promoter CTD PMID:22457795 cadmium dichloride increases expression ISO RGD:1623303 6480464 Cadmium Chloride results in increased expression of LY96 mRNA CTD PMID:26352046 calcitriol increases expression ISO RGD:1349135 6480464 Calcitriol results in increased expression of LY96 mRNA CTD PMID:21592394 calcitriol multiple interactions ISO RGD:1349135 6480464 [Testosterone co-treated with Calcitriol] results in increased expression of LY96 mRNA CTD PMID:21592394 carbon nanotube increases expression ISO RGD:1623303 6480464 Nanotubes, Carbon results in increased expression of LY96 mRNA CTD PMID:25554681 cobalt dichloride multiple interactions ISO RGD:1349135 6480464 cobaltous chloride results in increased activity of [TLR4 protein binds to LY96 protein] CTD PMID:25803856 cobalt dichloride increases expression EXP 6480464 cobaltous chloride results in increased expression of LY96 mRNA CTD PMID:24386269 copper atom multiple interactions ISO RGD:1349135 6480464 [NSC 689534 binds to Copper] which results in increased expression of LY96 mRNA CTD PMID:20971185 copper(0) multiple interactions ISO RGD:1349135 6480464 [NSC 689534 binds to Copper] which results in increased expression of LY96 mRNA CTD PMID:20971185 copper(II) sulfate increases expression ISO RGD:1349135 6480464 Copper Sulfate results in increased expression of LY96 mRNA CTD PMID:19549813 cyclosporin A increases expression ISO RGD:1349135 6480464 Cyclosporine results in increased expression of LY96 mRNA CTD PMID:20106945 more ... dexamethasone multiple interactions ISO RGD:1349135 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of LY96 mRNA CTD PMID:28628672 diarsenic trioxide multiple interactions ISO RGD:1349135 6480464 [Arsenic Trioxide co-treated with Bortezomib] results in increased expression of LY96 mRNA CTD PMID:25913414 diarsenic trioxide increases expression ISO RGD:1349135 6480464 Arsenic Trioxide results in increased expression of LY96 mRNA CTD PMID:26705709 , PMID:27829220 dioxygen multiple interactions ISO RGD:1623303 6480464 LY96 results in increased susceptibility to [Oxygen deficiency co-treated with Blood Glucose deficiency] CTD PMID:28063877 dorsomorphin multiple interactions ISO RGD:1349135 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LY96 mRNA CTD PMID:27188386 doxorubicin multiple interactions EXP 6480464 [Doxorubicin co-treated with Fungal Polysaccharides] results in decreased expression of LY96 mRNA CTD PMID:27181935 doxorubicin decreases expression ISO RGD:1349135 6480464 Doxorubicin results in decreased expression of LY96 mRNA CTD PMID:29803840 ethanol increases expression EXP 6480464 Ethanol results in increased expression of LY96 mRNA CTD PMID:28852734 ethanol multiple interactions EXP 6480464 platycodin D inhibits the reaction [Ethanol results in increased expression of LY96 mRNA] CTD PMID:28852734 ethyl methanesulfonate increases expression ISO RGD:1349135 6480464 Ethyl Methanesulfonate results in increased expression of LY96 mRNA CTD PMID:23649840 fluoranthene multiple interactions ISO RGD:1623303 6480464 [1-methylanthracene co-treated with fluoranthene] results in increased expression of LY96 mRNA CTD PMID:28329830 formaldehyde increases expression ISO RGD:1349135 6480464 Formaldehyde results in increased expression of LY96 mRNA CTD PMID:23649840 , PMID:27664576 gentamycin increases expression EXP 6480464 Gentamicins results in increased expression of LY96 mRNA CTD PMID:22061828 glycyrrhetinate multiple interactions ISO RGD:1623303 6480464 Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of [TLR4 protein binds to LY96 protein]] CTD PMID:28213090 glycyrrhetinic acid multiple interactions ISO RGD:1623303 6480464 Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of [TLR4 protein binds to LY96 protein]] CTD PMID:28213090 hydroquinone increases expression ISO RGD:1349135 6480464 hydroquinone results in increased expression of LY96 mRNA CTD PMID:31256213 indole-3-methanol affects expression EXP 6480464 indole-3-carbinol affects the expression of LY96 mRNA CTD PMID:21396975 indometacin multiple interactions ISO RGD:1349135 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of LY96 mRNA CTD PMID:28628672 lead diacetate increases expression ISO RGD:1623303 6480464 lead acetate results in increased expression of LY96 mRNA CTD PMID:20542052 lipopolysaccharide decreases response to substance ISO RGD:1349135 6480464 LY96 exon mutant form results in decreased susceptibility to Lipopolysaccharides, LY96 protein mutant form results in decreased susceptibility to Lipopolysaccharides CTD PMID:16367934 lipopolysaccharide affects binding ISO RGD:1349135 6480464 Lipopolysaccharides binds to LY96 protein CTD PMID:28063877 lipopolysaccharide increases response to substance ISO RGD:1623303 6480464 LY96 protein results in increased susceptibility to Lipopolysaccharides CTD PMID:16367934 lipopolysaccharide multiple interactions ISO RGD:1349135 6480464 1-(3 more ... CTD PMID:20700758 , PMID:28063877 melatonin multiple interactions EXP 6480464 Melatonin inhibits the reaction [tetrachlorobenzoquinone results in increased expression of LY96 protein] more ... CTD PMID:27413111 , PMID:28238930 mercury dichloride increases expression EXP 6480464 Mercuric Chloride results in increased expression of LY96 mRNA CTD PMID:16507785 methamphetamine increases expression ISO RGD:1349135 6480464 Methamphetamine results in increased expression of LY96 mRNA CTD PMID:25290377 methapyrilene decreases methylation ISO RGD:1349135 6480464 Methapyrilene results in decreased methylation of LY96 intron CTD PMID:30157460 methotrexate decreases expression ISO RGD:1349135 6480464 Methotrexate results in decreased expression of LY96 mRNA CTD PMID:17400583 methyl methanesulfonate increases expression ISO RGD:1349135 6480464 Methyl Methanesulfonate results in increased expression of LY96 mRNA CTD PMID:23649840 N-methylformamide affects expression ISO RGD:1623303 6480464 methylformamide affects the expression of LY96 mRNA, methylformamide analog affects the expression of LY96 mRNA CTD PMID:17040096 N-nitrosodiethylamine increases expression ISO RGD:1349135 6480464 Diethylnitrosamine results in increased expression of LY96 mRNA CTD PMID:21527772 N-nitrosodimethylamine increases expression EXP 6480464 Dimethylnitrosamine results in increased expression of LY96 mRNA CTD PMID:25380136 nickel dichloride multiple interactions ISO RGD:1349135 6480464 nickel chloride results in increased activity of [TLR4 protein binds to LY96 protein] CTD PMID:25803856 paracetamol affects expression ISO RGD:1623303 6480464 Acetaminophen affects the expression of LY96 mRNA CTD PMID:17562736 paracetamol multiple interactions ISO RGD:1623303 6480464 PANX1 gene mutant form inhibits the reaction [Acetaminophen results in increased expression of LY96 mRNA] CTD PMID:29246445 paracetamol increases expression ISO RGD:1623303 6480464 Acetaminophen results in increased expression of LY96 mRNA CTD PMID:29246445 paracetamol decreases expression ISO RGD:1349135 6480464 Acetaminophen results in decreased expression of LY96 mRNA CTD PMID:21420995 , PMID:26690555 phenobarbital multiple interactions ISO RGD:1623303 6480464 NR1I3 protein affects the reaction [Phenobarbital results in increased expression of LY96 mRNA] CTD PMID:19482888 phenobarbital increases expression ISO RGD:1623303 6480464 Phenobarbital results in increased expression of LY96 mRNA CTD PMID:19270015 , PMID:19482888 phenylmercury acetate multiple interactions ISO RGD:1349135 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LY96 mRNA CTD PMID:27188386 platycodin D multiple interactions EXP 6480464 platycodin D inhibits the reaction [Ethanol results in increased expression of LY96 mRNA] CTD PMID:28852734 prednisolone decreases expression ISO RGD:1349135 6480464 Prednisolone results in decreased expression of LY96 mRNA CTD PMID:17379860 propanal increases expression ISO RGD:1349135 6480464 propionaldehyde results in increased expression of LY96 mRNA CTD PMID:26079696 quercetin increases expression ISO RGD:1349135 6480464 Quercetin results in increased expression of LY96 mRNA CTD PMID:21632981 SB 431542 multiple interactions ISO RGD:1349135 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LY96 mRNA CTD PMID:27188386 silicon dioxide increases expression ISO RGD:1349135 6480464 Silicon Dioxide analog results in increased expression of LY96 mRNA, Silicon Dioxide results in increased expression of LY96 mRNA CTD PMID:25351596 , PMID:25895662 silver atom increases expression ISO RGD:1349135 6480464 Silver results in increased expression of LY96 mRNA CTD PMID:22342292 silver(0) increases expression ISO RGD:1349135 6480464 Silver results in increased expression of LY96 mRNA CTD PMID:22342292 sodium arsenite increases expression ISO RGD:1349135 6480464 sodium arsenite results in increased expression of LY96 mRNA CTD PMID:23876855 , PMID:29301061 sodium arsenite decreases expression ISO RGD:1623303 6480464 sodium arsenite results in decreased expression of LY96 mRNA CTD PMID:31233874 sodium dichromate decreases expression ISO RGD:1349135 6480464 sodium bichromate results in decreased expression of LY96 mRNA CTD PMID:17685462 succimer multiple interactions ISO RGD:1349135 6480464 [Succimer co-treated with Magnetite Nanoparticles] results in increased expression of LY96 mRNA CTD PMID:26378955 tert-butyl hydroperoxide multiple interactions ISO RGD:1349135 6480464 1-(3 more ... CTD PMID:28063877 , PMID:29111459 testosterone multiple interactions ISO RGD:1349135 6480464 [Testosterone co-treated with Calcitriol] results in increased expression of LY96 mRNA CTD PMID:21592394 testosterone increases expression ISO RGD:1349135 6480464 Testosterone results in increased expression of LY96 mRNA CTD PMID:21592394 tetrachloromethane increases expression ISO RGD:1623303 6480464 Carbon Tetrachloride results in increased expression of LY96 mRNA CTD PMID:27339419 tetrachloromethane decreases expression ISO RGD:1623303 6480464 Carbon Tetrachloride results in decreased expression of LY96 mRNA CTD PMID:29987408 tetrachloromethane multiple interactions ISO RGD:1623303 6480464 [PANX1 protein co-treated with Carbon Tetrachloride] affects the expression of LY96 mRNA CTD PMID:29987408 thalidomide decreases expression ISO RGD:1623303 6480464 Thalidomide results in decreased expression of LY96 mRNA CTD PMID:26006729 , PMID:26217789 titanium dioxide increases expression ISO RGD:1623303 6480464 titanium dioxide results in increased expression of LY96 mRNA CTD PMID:23557971 tris(2-butoxyethyl) phosphate affects expression ISO RGD:1349135 6480464 tris(2-butoxyethyl) phosphate affects the expression of LY96 mRNA CTD PMID:29024780 troglitazone increases expression ISO RGD:1349135 6480464 troglitazone results in increased expression of LY96 mRNA CTD PMID:25572481 tungsten increases expression ISO RGD:1623303 6480464 Tungsten results in increased expression of LY96 mRNA CTD PMID:30912803 valproic acid decreases expression ISO RGD:1349135 6480464 Valproic Acid results in decreased expression of LY96 mRNA CTD PMID:29154799 vincristine increases expression ISO RGD:1349135 6480464 Vincristine results in increased expression of LY96 mRNA CTD PMID:23649840 zinc atom affects expression ISO RGD:1349135 6480464 Zinc affects the expression of LY96 mRNA CTD PMID:16979875 zinc(0) affects expression ISO RGD:1349135 6480464 Zinc affects the expression of LY96 mRNA CTD PMID:16979875
Gene-Chemical Interaction Annotations
